Skip to Content

Invesco Health Care C GTHCX

Medalist Rating as of | See Invesco Investment Hub
  • NAV / 1-Day Return 19.15  /  −0.62 %
  • Total Assets 1.3 Bil
  • Adj. Expense Ratio
    1.810%
  • Expense Ratio 1.810%
  • Distribution Fee Level Below Average
  • Share Class Type Level Load
  • Category Health
  • Investment Style Large Growth
  • Min. Initial Investment 1,000
  • Status Open
  • TTM Yield
  • Turnover 59%

USD | NAV as of Apr 15, 2024 | 1-Day Return as of Apr 15, 2024, 11:13 PM GMT+0

Morningstar’s Analysis GTHCX

Will GTHCX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Invesco Health Care C earns a Morningstar Medalist Rating of Negative with strength in areas such as People offset by weaker spots such as Process.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the most expensive quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings GTHCX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 45.0
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

8.94 120.9 Mil
Healthcare

UnitedHealth Group Inc

6.17 83.5 Mil
Healthcare

Boston Scientific Corp

5.16 69.8 Mil
Healthcare

McKesson Corp

4.07 55.1 Mil
Healthcare

Vertex Pharmaceuticals Inc

3.73 50.5 Mil
Healthcare

Regeneron Pharmaceuticals Inc

3.55 48.0 Mil
Healthcare

Merck & Co Inc

3.54 47.9 Mil
Healthcare

Stryker Corp

3.48 47.0 Mil
Healthcare

Thermo Fisher Scientific Inc

3.16 42.7 Mil
Healthcare

Intuitive Surgical Inc

3.16 42.7 Mil
Healthcare